Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified Starting Dosage of Avatrombopag in ITP
NCT07133659Phase 4Recruiting
- Sponsor
- Al-Mustansiriyah University
- Start
- Jun 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of avatrombopag in immune thrombocytopenia (ITP), sponsored by Al-Mustansiriyah University. Started Jun 2025; status: recruiting.
02
Drugs
avatrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07133659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07133659.